Comparison of Treatment Guidelines for Ulcerative Colitis: Role of Biologics / 대한소화기학회지
The Korean Journal of Gastroenterology
;
: 192-195, 2018.
Article
Dans Coréen
| WPRIM
| ID: wpr-713781
ABSTRACT
Ulcerative colitis (UC) is a chronic inflammatory condition of the colon, characterized by diffuse mucosal inflammation with bloody diarrhea. The therapeutic goals in UC have evolved from symptomatic relief to deep remission, including sustained steroid-free clinical remission, mucosal healing, and ideally histologic remission. The management of UC has significantly been improved by advance of biologic agents including anti-tumor necrosis factor alpha (TNF-α) antibodies. Anti-TNF-α agent have progressively been introduced earlier in treatment algorithms for UC in order to minimize steroid exposure and dependence and to maximize disease control and quality of life. We reviewed the therapeutic recommendations of biologic agents for UC in the Korean and European Crohn's and Colitis Organization guidelines.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Qualité de vie
/
Ulcère
/
Produits biologiques
/
Facteurs biologiques
/
Rectocolite hémorragique
/
Facteur de nécrose tumorale alpha
/
Colite
/
Côlon
/
Diarrhée
/
Inflammation
Type d'étude:
Guide de pratique
langue:
Coréen
Texte intégral:
The Korean Journal of Gastroenterology
Année:
2018
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS